No abstract available.
Cell Line, Tumor* ; Doxorubicin* ; Epirubicin* ; Humans*

No abstract available.
Doxorubicin* ; Euonymus*

No abstract available.
Doxorubicin* ; Etoposide* ; Stomach Neoplasms*

No abstract available.
Doxorubicin* ; Myocytes, Cardiac*

No abstract available.
Cardiomyopathy, Dilated* ; Doxorubicin

No abstract available.
Animals ; Doxorubicin* ; Rats*

No abstract available.
Doxorubicin* ; Incidence* ; Stroke Volume*

Introduction: Doxorubicin (DOX) and paclitaxel (PTX) are both widely used anticancer drugs with a broad spectrum of antitumor activity, commonly against breast, ovarian, and lung cancers. Currently, these drugs are commercially available in liposomal formulations for their use in chemotherapy. This study generally proposed coconut oil bodies (COB) obtained from Cocos nucifera L. as an alternative carrier for DOX and PTX rather than the currently used liposome. Objectives: This study aimed to compare standard liposome and coconut oil bodies as drug carriers in terms of their microencapsulation efficiencies, lipid profiles, in vitro drug release and stability, as well as their cholesterol levels. Methods: Coconut oil bodies (COB) were isolated and purified from Cocos nucifera L. by modified sucrose gradient method followed by microencapsulation of standard drugs (doxorubicin and paclitaxel) through selfassembly and freeze-thaw method. The two standard drugs were encapsulated using COB and standard liposome. Encapsulation efficiency of both materials were determined. Lipid profiles of both encapsulating materials were analyzed by Fourier-transform infrared spectroscopy, gas chromatography-flame ionization detector, and cholesterol level determination. In vitro drug release and pH stability of both encapsulated drugs were analyzed. Results: Doxorubicin (DOX) and paclitaxel (PTX) were successfully incorporated in COB. Lauric acid was mainly abundant in COB and was able to lower cholesterol levels (5 mg/dL). COB incorporated with DOX and PTX showed stability at acidic and neutral pH. Drug release profile showed a rapid outburst within 3 hours compared to liposome encapsulated DOX and PTX. Conclusion Our study showed the encouraging potentials of using COB as wall materials that will make them attractive candidates for the formulation of pharmaceuticals for optimized drug delivery of cancer chemotherapeutics DOX and PTX
Liposomes ; Doxorubicin ; Paclitaxel

PURPOSE: Breast cancer is heterogeneous disease and the response to chemotherapeutic agents is also heterogeneous from patient to patient. Chemotherapy response assay is in vitro test that is performed to evaluate the degree of tumor growth inhibition by chemotherapy drugs. In this study, we performed the chemotherapy response assay using adenosine triphosphate (ATP-CRA) in breast cancer patients and assessed the clinical availability. METHODS: Sixty five breast cancer patients were enrolled in this study. Cancer cells were evenly divided and treated with commonly used chemotherapeutic drugs in breast cancer (doxorubicin, epirubicin, 5-fluorouracil, paclitaxel, docetaxel, vinorelbine, and gemcitabine). To verify in vitro ATP-CRA indirectly, we analyzed the correlation between cell death rate (CDR) of doxorubicin and epirubicin, and between doxorubicin and paclitaxel. We also analyzed the mean CDR of doxorubicin, epirubicin and paclitaxel by HER2 status. RESULTS: We could successfully perform the ATP-CRA in 60 patients (95.2%). In all cases, we can get the results within 7 days. The range of CDR was very wide, from 0 to more than 50%, except gemcitabine. Epirubicin showed the highest mean CDR (39.9%) and doxorubicin, paclitaxel in order. According to the chemosensitivity index, paclitaxel is the most frequently first-ranked and doxorubicin, epirubicin in order. Correlation coefficient between the cell death rate of doxorubicin and epirubicin is 0.4210 and 0.1299 between paclitaxel and doxorubicin. In HER2 positive group, mean CDR of paclitaxel, epirubicin and doxorubicin was higher than in HER2 negative group, even though epirubicin and doxorubicin were not statistically significant (p=0.018, p=0.114, p=0.311, respectively). CONCLUSION: ATP-CRA showed heterogeneous results in individual patients. ATP-CRA was successful and can be performed within short time period. According to our in vitro study, it showed similar results with in vivo study but for the clinical use, the prospective randomized controlled trial should be preceded.
Adenosine Triphosphate ; Breast ; Breast Neoplasms ; Cell Death ; Deoxycytidine ; Doxorubicin ; Epirubicin ; Fluorouracil ; Humans ; Paclitaxel ; Polyphosphates ; Taxoids ; Vinblastine

PURPOSE: Breast cancer ranks as the second most frequent cancer in women in Korea, and the rate is gradually increasing. Compared to European countries and USA., the Korean breast cancer occurs at a younger age (mean age: 47) than in western countries (mean age: 60). We suppose that there is some biological differences between Korean and western breast cancer. This study was designed to determine the target chemotherapy agents for use on individual patients and define target patients for chemotherapy during the post-op period. Additionally, we desired to acquire primary data for further proteomic analysis of patients. METHODS: Twenty-one patients with breast cancer were entered in this study. Tumor specimens were taken and informed consent was obtained for use of the samples in drug sensitivity testing. MTS[3-(4,5-dimethylthiazol-2-yl)-5- (3-carboxy methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] assay was able to be preformed in 16 patients (success rate, 76.2 percent). We used four drugs including Adriamycin, Epirubicin, 5-FU, and Taxol. RESULTS: In the axillary lymph node negative group, 5-FU (56.62%) and Taxol (53.85%) were sensitive drugs. There were no sensitive drugs in the p53 over-expression group. In the wild p53 group, 5-FU was the only sensitive drug. 5-FU was sensitive in both the ER and PR positive groups. Taxol was sensitive in the c-erbB2 low expression group. CONCLUSION: We obtained the results for chemosensitivity of breast cancer of Korean women. 5-FU and Taxol were relatively sensitive drugs, however we believe further data should be collected and added to obtain complete chemosensitivity results.
Breast Neoplasms* ; Breast* ; Doxorubicin ; Drug Therapy ; Epirubicin ; Female ; Fluorouracil ; Humans* ; Informed Consent ; Korea ; Lymph Nodes ; Paclitaxel